WCLC 2025 - Posters & ePosters-P2.08 .38 Identifying Risk Factors for Recurrence in Non-Small Cell Lung Cancer Patients With Pcr After Neoadjuvant Immunochemotherapy

P2.08 .38 Identifying Risk Factors for Recurrence in Non-Small Cell Lung Cancer Patients With Pcr After Neoadjuvant Immunochemotherapy

Back to course

Pdf Summary

This study by Dongmei Lin et al. from Peking University Cancer Hospital investigates risk factors for recurrence in non-small cell lung cancer (NSCLC) patients who achieved pathological complete response (pCR) after neoadjuvant immunochemotherapy. Although pCR generally predicts favorable prognosis, some patients still experience post-surgical recurrence, and factors contributing to this remain poorly understood.<br /><br />A retrospective analysis was conducted on 116 NSCLC patients meeting the inclusion criterion of pCR post-neoadjuvant chemoimmunotherapy. Multiple methodologies were employed: bulk RNA sequencing of preoperative specimens, multiplex immunofluorescence of postoperative samples, preoperative PET-CT imaging, and PD-L1 expression assessments.<br /><br />RNA sequencing identified five differentially expressed genes (DEGs) distinguishing recurrent from non-recurrent cases. Univariate survival analysis further linked four genes—ITGA8, NRG1, PLEKHG6, and PLA2G4C—to prognosis. While immune-related gene expression profiles did not correlate with recurrence, tumor microenvironment (TME) factors, specifically cancer-associated fibroblasts, neutrophils, and epithelial-mesenchymal transition (EMT), showed significant associations.<br /><br />Analysis of preoperative PET-CT scans determined an optimal standard uptake value (SUV) cut-off of 12.9, which stratified patients into groups with significantly different survival outcomes. Pretreatment lymph node metastasis was also a strong predictor of recurrence, with preoperative lymph node status yielding an area under the ROC curve (AUC) of 0.764.<br /><br />In conclusion, this study identifies molecular (specific gene expression), microenvironmental (fibroblasts, neutrophils, EMT), metabolic (PET SUV), and clinical (lymph node status) factors as linked to recurrence risk in NSCLC patients with pCR after neoadjuvant immunochemotherapy. These findings may inform tailored surveillance and therapeutic strategies post-surgery to mitigate recurrence risk.

Asset Subtitle

Dongmei Lin

Meta Tag

Speaker Dongmei Lin

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

non-small cell lung cancer

NSCLC

pathological complete response

pCR

neoadjuvant immunochemotherapy

tumor microenvironment

cancer-associated fibroblasts

epithelial-mesenchymal transition

PET-CT SUV

lymph node metastasis